Alex Michael Azar II (; born June 17, 1967) is an American attorney, businessman, lobbyist, and former pharmaceutical executive who served as the 24th U.S. secretary of health and human services from 2018 to 2021. He was also chairman of the White House Coronavirus Task Force from its inception in January 29, 2020 to February 26, 2020, when he was replaced by Vice President Mike Pence.
In 2021, he was appointed a senior executive in residence at the Miami Herbert Business School at the University of Miami.
From 2012 to 2017, Azar was president of the U.S. division of Eli Lilly and Company, a major drug company, and a member of the board of directors of the Biotechnology Innovation Organization, a large pharmaceutical trade association.
Azar served as general counsel of the U.S. Department of Health and Human Resources (HHS) from 2001 to 2005. On July 22, 2005, he was confirmed as the deputy secretary of health and human services; he served in that capacity until his January 2007 resignation.
Azar attended Parkside High School in Salisbury, Maryland, where he graduated in 1985. He received a B.A. degree Latin honors in government and economics from Dartmouth College in 1988. He belonged to the Kappa Kappa Kappa fraternity. He earned a Juris Doctor degree from Yale Law School in 1991, where he served as a member of the executive committee of the Yale Law Journal.
From 1994 to 1996, he served as an associate independent counsel for Ken Starr in the United States Office of the Independent Counsel, where he worked on the first two years of the investigation into the Whitewater controversy. At the time of Azar's appointment, he was working as an associate in Starr's law firm.
Between 1996 and 2001, Azar worked for Wiley Rein, a Washington, D.C., law firm, where he achieved partner status.
Working under Secretary Mike Leavitt, Deputy Azar supervised the operation of HHS, which would grow to an annual budget of over $1 trillion by 2017 when he was appointed secretary. Azar led the development and approval of HHS regulations, led U.S. government efforts to encourage worldwide pharmaceutical and medical device innovation, and was in charge of the HHS response to an initiative implemented by President George W. Bush to improve government performance. Azar resigned in January 2007.
In April 2009, Azar became vice president of Lilly's U.S. Managed Healthcare Services organization and its Puerto Rico affiliate. In 2009, the company paid $1.415 billion to settle criminal charges regarding its promotion of antipsychotic drug Zyprexa (olanzapine) for between 1999 and 2005.
Effective January 1, 2012, Azar became president of Lilly USA, LLC, the largest division of Eli Lilly and Company, and was responsible for the company's entire operations in the United States. Prices for drugs rose substantially under Azar's leadership, including the tripling of the cost of the company's top-selling insulin drug. Also under Azar's watch, Eli Lilly was one of three companies accused in a class-action lawsuit of exploiting the drug pricing system to increase profits for insulin. Eli Lilly was also fined in Mexico for colluding on the price of insulin.
In connection with the position, Azar served on the board of directors of the Biotechnology Innovation Organization, a pharmaceutical lobby.
In January 2017, Azar resigned from Eli Lilly "to pursue other career opportunities" as a result of a company reorganization. He also resigned from the board of directors of the Biotechnology Innovation Organization. In his last year at the corporation he earned $2 million. Cronyism and Conflicts of Interest In Trump's Coronavirus Task Force , The Intercept, Sharon Lerner, February 29, 2020. Retrieved March 12, 2020.
Many health care advocates raised concerns about the nomination, citing Azar's track record of raising drug prices and his opposition to Obamacare. Advocacy Groups Slam Azar Ahead of Committee Hearing , HEALTHCAREDIVE, David Lim, January 4, 2018. Retrieved February 28, 2020. Critics noted that Azar approved a tripling of the price of insulin while vice president of Managed Healthcare Services of Eli Lilly. HHS Secretary Alex Azar now wants the Trump administration to import cheaper drugs from Canada , Newsweek, Alexandra Hutzler, July 31, 2019. Retrieved February 28, 2020. Speaking in favor of his nomination were two former U.S. Senate majority leaders, Democrat Tom Daschle and Republican Bill Frist. Both those endorsers were affiliated with the Bipartisan Policy Center, a Washington, D.C., think-tank which receives support from Eli Lilly. "Pundits Funded by Drug Company Applaud Its Takeover of Trump Health Department" , The Intercept, Zaid Jilani, November 29, 2017. Retrieved March 12, 2020.
In spite of objections, his nomination was relatively smooth. Azar was confirmed on January 24, 2018, with a vote of 55–43, with most Democrats opposed. Voting against him, Oregon senator Ron Wyden, ranking member on the Senate Finance Committee, said that while Azar was at Eli Lilly, he "never, not one time, signed off on a decrease in the price of a drug." "Meet HHS Secretary Alex Azar, the Official Chairing the Coronavirus Task Force" , Time, Tessa Berenson, February 27, 2020. Retrieved February 28, 2020. Senator Bernie Sanders said in a press release, "The nomination of Alex Azar, the former head of Eli Lilly's U.S. operations, shows that Trump was never serious about his promise to stop the pharmaceutical industry from 'getting away with murder'." "The last thing we need is to put a pharmaceutical executive in charge of the Department of Health and Human Services." During that tenure, Eli Lilly was fined for colluding to maintain high drug costs in Mexico. What You Need to Know about Alex Azar, Trump's HHS Nominee , Scientific American, Dina Fine Maron, November 28, 2017. Retrieved March 10, 2020.
Azar had additionally consulted with numerous other biopharmaceutical and health insurance corporations regarding government policy, product access, sales and marketing, pricing, reimbursement, and distribution. He was confirmed by the Senate on January 24, 2018, and sworn in by Vice President Pence on January 29, 2018.
From March to December 2018, Azar sat on the Federal Commission on School Safety.
Azar had prolonged disputes with Seema Verma, who was Trump's administrator of the Centers for Medicare & Medicaid Services (CMS). She accused Azar and his HHS predecessor, Tom Price, of sexist management; an inquiry by a former Trump HHS official, Heather Flick, concluded that Azar had not discriminated. Azar was widely reported to spar with his subordinates, leading to criticism of his handling of the COVID-19 pandemic response.
On January 20, 2021, immediately after the end of the Trump administration, China sanctioned Azar and other Trump administration officials. The sanctioned people cannot travel to China and cannot do business with China. President Biden's National Security Council called the sanctions "unproductive and cynical."
At the time, Azar said, there were just five confirmed cases in the U.S., there was no known person-to-person transmission, and every confirmed U.S. victim had traveled to Wuhan, China, the outbreak's place of origin. "This is potentially a very serious public health threat, but at this time Americans should not worry about their own safety", Azar said. At that point, the disease had killed at least 106 people in China, with more than 4,500 cases confirmed. What the best public health minds know — and don't know — about Wuhan coronavirus , Politico, Joanne Kenen, January 28, 2020. Retrieved February 28, 2020. On January 29, 2020, Azar told Trump that the COVID-19 epidemic was under control.
However, two days later, on January 31, 2020, Azar declared a public health emergency. The determination that a public health emergency existed from COVID-19 was renewed in April, July, and October 2020, and in January 2021.
On February 27, U.S. representative Jimmy Gomez of California revealed that he had been contacted by a whistleblower from the Department of Health and Human Services (HHS) who had been dispatched to deal with the arrivals of travelers exposed to the coronavirus. There were allegations made that those sent from the HHS to California quarantine sites lacked both sufficient protective clothing and the training necessary to prepare them to deal with the contagion, though they were working alongside CDC personnel who wore adequate protective gear. Whistleblower Feds helping evacuees lacked virus protection , The Washington Post, Ricardo Alonso-Zaldivar (AP), February 27, 2020. Retrieved February 28, 2020. The whistleblower also said that professionals raising concerns about the unsafe practices were subjected to retaliation.
Azar responded to the issues raised by Gomez, saying, "Urgency does not compensate for violating isolation and quarantine protocols" and adding, "I'd want to know the full facts and would take appropriate remedial measures." Coronavirus updates: WHO increases risk to 'very high,' tells governments to 'wake up' , USA Today, Adrianna Rodriguez, February 28, 2020. Retrieved February 28, 2020. Azar insisted that careful protocols were being observed by all CDC employees.
On February 28, 2020, United States Senate Finance Committee ranking member Ron Wyden wrote Azar to ask why employees of the HHS Administration for Children and Families were involuntarily dispatched to California to meet with quarantined travelers despite lacking expertise in the field and lacking proper information, equipment, and training. Wyden also asked why said employees were not cleared to ensure that they had not become carriers of the disease before they were returned to their home stations. Sen. Ron Wyden asks HHS how agency employees are tested for coronavirus , Axios, Orion Rummler, February 28, 2020. Retrieved February 29, 2020.
On April 25, 2020, multiple media outlets reported that the White House was weighing a plan to oust Azar due to frustrations over his response to the COVID-19 pandemic.
The following day, President Trump tweeted that such reports were "fake news" and that he has no plans to replace Azar.
Azar picked Brian Harrison, a 37-year old former Labradoodle breeder who had no formal education in public health or related fields, but who had worked in the HHS for six years, as HHS's main coordinator for the government's response to the coronavirus.
Chad Wolf said that the fatality rate for COVID-19 was between 1.5% and 2%, and said incorrectly that the fatality rate for influenza over the last 10 years in America was similar (about 2%). Kennedy was unhappy with the briefing, saying afterward, "I thought a lot of the briefing was bullshit ... They would answer the question but dodge, bob, and weave. I understand there's a lot they don't know. I get that. But they need to answer the questions straight up. They all talk about a task force, a committee – a committee's not going to solve this problem."
Trump's officials tried to allay concerns that their request for $2.5 billion was insufficient to address the epidemic. Some Republicans joined Democrats in criticizing the funds requested and found transparency lacking with regard to a coherent strategy to contain the virus. Another Republican, Senate Appropriations Committee chairman Richard Shelby of Alabama, told Azar: "If you lowball something like this, you'll pay for it later." Coronavirus triggers swift bipartisan backlash against Trump , Politico, Rachel Roubein and Alice Miranda Ollstein, February 25, 2020. Retrieved February 26, 2020. Coronavirus's spread in U.S. is 'inevitable,' CDC warns , The Washington Post, Erica Werner, Yasmeen Abutaleb, Lena H. Sun, and Lenny Bernstein, February 25, 2020. Retrieved February 26, 2020. Pennsylvania Democratic congressman Brendan Boyle asked Azar how he could defend "draconian cuts" in the CDC budget "at the same time we are facing a unique worldwide health crisis."
Two years earlier, a coalition of global health organizations opposed Trump's plans to reduce the CDC's operations in 39 of 49 countries in which it had been helping to rapidly identify and suppress outbreaks of diseases. The coalition wrote to Azar, contending, "These programs are essential to our national defense". Trump says he can bring in coronavirus experts quickly. The experts say it's not that simple , The Washington Post, Beth Reinhard, Emma Brown, and Neena Satija February 27, 2020. Retrieved February 29, 2020. White House sidelines Azar from coronavirus response , Politico, Dan Diamond, Sarah Owermohle, and Meridith Mcgraw, March 5, 2020. Retrieved March 11, 2020. In 2018, National Security Advisor John Bolton dismantled the task force charged with responsibility for planning and response to epidemics. The team's leader, Rear Admiral Timothy Ziemer, was the leader of the anti-malarial efforts under presidents Barack Obama and George W. Bush. White House Homeland Security Advisor Tom Bossert, who had advocated a comprehensive biodefense strategy against both pandemics and potential biological attacks, departed from the White House on the same day Bolton arrived.
On January 12, 2021, Azar announced that HHS would be releasing remaining stockpiles of vaccine to states; however, at the time of the announcement, all stockpiles had already been exhausted. This was met with confusion and anger from various governors.
Azar said the trip was to convey Trump's support for Taiwan's leadership in global health, reiterate U.S. support for Taiwan, and cooperate on global health and health safety issues. The next day, he signed a memorandum of understanding on Medical and Health Cooperation in Taipei.
On January 20, 2021, the Government of China imposed sanctions against Azar, outgoing U.S. secretary of state Mike Pompeo, former under secretary of state Keith J. Krach, outgoing U.S. ambassador to the United Nations Kelly Craft, and 24 other former Trump officials. Biden's National Security Council called the sanctions "unproductive and cynical."
Before his nomination, he lived in Indianapolis with his wife and two children. Azar served for two years on the board of HMS Holdings. He is currently on the board of the American Council on Germany, where he is chairman of the Strategic Planning Committee, and the Indianapolis Symphony Orchestra.
He has previously served on the board of directors of the Healthcare Leadership Council, where he was treasurer; the National Association of Manufacturers; and the Indianapolis International Airport Authority, where he was chairman of the Human Resources Committee.
In 2020, Azar revealed he has Coeliac disease while discussing a U.S. Food and Drug Administration rule related to Gluten-free diet labeling for fermented foods.
|-
|-
|-
Eli Lilly and Company
Secretary of Health and Human Services (2018–2021)
Nomination and confirmation
Healthcare policy
Security Strategy
Affordable Care Act
Abortion
Regulations
COVID-19
Outbreak
Centers for Disease Control and Prevention
Congressional testimony and requests for funding
HHS purchase of 500,000 doses of remdesivir
Testing
Vaccine
Rule ban
Taiwan visit
Resignation letter
COVID-19 lawsuit
Personal life
Politics
See also
External links
|
|